In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging
暂无分享,去创建一个
Jason R. Gunn | Brian W. Pogue | Tayyaba Hasan | Kenneth M. Tichauer | Kimberley S. Samkoe | Kristian J. Sexton | Shannon K. Hextrum | B. Pogue | T. Hasan | K. Tichauer | J. Gunn | K. Samkoe | Harold H. Yang | W. Klubben | W. Spencer Klubben
[1] Tayyaba Hasan,et al. Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. , 2010, Academic radiology.
[2] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[3] P. Lambin,et al. Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET , 2008, Journal of Nuclear Medicine.
[4] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[5] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] M. Korc,et al. Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[7] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] L. Norton,et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Bart Cornelissen,et al. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[10] Sergio Fantini,et al. Near-infrared absorption and scattering spectra of tissues in vivo , 1999, Photonics West - Biomedical Optics.
[11] R. McLendon,et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.
[12] Vincent J. Cunningham,et al. Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.
[13] R. Weissleder,et al. Fluorescence molecular tomography resolves protease activity in vivo , 2002, Nature Medicine.
[14] R K Jain,et al. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.
[15] J N Weinstein,et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] A. Lammertsma,et al. Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.
[17] Tayyaba Hasan,et al. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. , 2010, International journal of radiation oncology, biology, physics.
[18] Brian W. Pogue,et al. High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas , 2011, Molecular Imaging and Biology.
[19] Christopher H Contag,et al. Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. , 2009, Biophysical journal.
[20] Tayyaba Hasan,et al. Imaging targeted-agent binding in vivo with two probes. , 2010, Journal of biomedical optics.
[21] E. Kim,et al. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. , 1980, Cancer research.
[22] Vladimir Tolmachev,et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[23] R. Weissleder,et al. Imaging in the era of molecular oncology , 2008, Nature.
[24] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[25] S. Wise. Nanocarriers as an emerging platform for cancer therapy , 2007 .
[26] V. Chernomordik,et al. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. , 2009, Molecular imaging.
[27] R. Weissleder,et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.
[28] A. Bradwell,et al. Radioimmunodetection of gastrointestinal neoplasms with antibodies to carcinoembryonic antigen. , 1980, Cancer research.